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Background. Contemporary antiretroviral treatment regimens are simpler than in the past, with lower pill burden
and once-daily dosing frequency common. We performed a meta-analysis of randomized controlled trials (RCTs) to
investigate the impact of pill burden and once-daily vs twice-daily dosing on ART adherence and virological outcomes.
Methods. A literature search of 4 electronic databases through 31 March 2013 was used. RCTs comparing once-
daily vs twice-daily ART regimens that also reported on adherence and virological suppression were included. Study
design, study population characteristics, intervention, outcome measures, and study quality were extracted. Study qual-
ity was rated using the Cochrane risk-of-bias tool.
Results. Nineteen studies met our inclusion criteria (N = 6312 adult patients). Higher pill burden was associated
with both lower adherence rates (P = .004) and worse virological suppression (P < .0001) in both once-daily and twice-
daily subgroups, although the association with adherence in the once-daily subgroup was not statistically signiﬁcant.
The average adherence was modestly higher in once-daily regimens than twice-daily regimens (weighted mean diffe-
rence = 2.55%; 95% conﬁdence interval [CI], 1.23 to 3.87; P = .0002). Patients on once-daily regimens did not achieve
virological suppressionmore frequently than patients on twice-daily regimens (relative risk [RR] = 1.01; 95% CI, 0.99 to
1.03; P = .50). Both adherence and viral load suppression decreased over time, but adherence decreased less with once-
daily dosing than with twice-daily dosing.
Conclusions. Lower pill burden was associated with both better adherence and virological suppression. Adherence,
but not virological suppression, was slightly better with once- vs twice-daily regimens.
Keywords. randomized controlled trials; ART; ﬁxed-dose combination; once-daily; twice-daily.
Among human immunodeﬁciency virus (HIV)–infected
patients, adherence to antiretroviral therapy (ART) is a
primary determinant of virological suppression, disease
progression, and death [1–3]. ART regimens are now
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simpler than they were in the past, with lower pill burden and
dosing frequency; they have also become less toxic and better tol-
erated [4]. In 2006, tenofovir–emtricitabine–efavirenz became
the ﬁrst approved branded, ﬁxed-dose, single-tablet regimen
(STR) [5,6].Two other STRswere subsequently approved by the
US Food and Drug Administration: tenofovir–emtricitabine–
rilpivirine and tenofovir–emtricitabine–elvitegravir–cobicistat
[7, 8], both of which are currently recommended by the US De-
partment of Health and Human Services [9].
Little is known about the impact of once- vs twice-daily ART
and pill burden on adherence and virological outcomes. Indeed,
in some patients with suboptimal adherence and/or virological
failure, reducing the pill burden may be more important than
switching from a twice-daily regimen to a once-daily regimen.
Furthermore, governments, third-party payers, and HIV pro-
grams may prefer the use of non-coformulated ART generics
because they are less expensive than brand name STRs. There-
fore, as more generics become available, there is the potential
for a paradoxical “desimpliﬁcation,” with movement away
from STR regimens [10, 11].
A 2009 meta-analysis by Parienti and colleagues of 11 ran-
domized trials reported that ART adherence rates were signiﬁ-
cantly better with once-daily than with twice-daily regimens
[12], with a modest effect that was more pronounced at the
time of treatment initiation and was not observed in ART-
experienced patients. However, that study did not ﬁnd a signiﬁ-
cant effect of once-daily vs twice-daily regimens on virological
outcome, possibly because of insufﬁcient statistical power [13].
Since 2009, more randomized clinical trials comparing once- vs
twice-daily regimens have been published, allowing a pooled
meta-analysis with greater power to reinvestigate this question
as well as the impact of pill burden [14–26]. Also, these more
recent trials investigated better-tolerated, more contemporary
regimens that are currently in wide clinical use.
Thus, we conducted an updated meta-analysis to evaluate the
impact of pill burden and once- vs twice-daily ART on adher-
ence as well as virological outcomes in both ART-naive and
-experienced HIV-infected adults.
METHODS
Protocol and Registration
The study background, rationale, and methods were speciﬁed in
advance and documented in a protocol that was published in
the PROSPERO register (CRD42012002515).
Inclusion Criteria
We included only randomized controlled trials (RCTs) that
compared once-daily vs twice-daily regimens in either ART-
naive or -experienced patients with objective measures of ad-
herence and measures of virological outcomes.
Search Strategy
We systematically searched the following databases from their
inception until 31 March 2013 (including those years searched
by the Parienti meta-analysis): Cochrane CENTRAL, PubMed,
Google scholar, and Web of Science. Our search terms in-
cluded the following: “HIV,” “treatment simpliﬁcation,” “co-
formulation,” “ﬁxed-dose combination,” “QD,” “twice-daily,”
“once-daily,” “adherence,” “HAART,” “ART,” “cART,” and “pa-
tient preference.” We also searched abstracts from major HIV/
AIDS and infectious diseases conferences (from 2008 onward)
including Conference on Retrovirus and Opportunistic Infec-
tions, International AIDS Conference, International AIDS
Society Conference on HIV Treatment, Pathogenesis and Pre-
vention, International Conference on Antimicrobial Agents
and Chemotherapy, and Infectious Diseases Society of America
Conference. In addition, the bibliographies of relevant review
articles, metaanalyses, and selected articles were examined for
pertinent studies.
Study Selection
We evaluated each identiﬁed study using the following prede-
termined selection criteria: open-label RCTs of HIV-infected
subjects either ART naive or ART experienced that compared
once-daily ART regimens with any twice-daily antiretroviral
regimens and assessed both adherence (using objective mea-
sures, such as pill count or medication event monitoring system
[MEMS]) and viral suppression (percentage of subjects with
HIV-1 RNA levels < 50 copies/mL or < 200 copies/mL in
the intent-to-treat, missing-equals-failure analysis). Placebo-
controlled, blinded trials were excluded because the regimen
frequency was identical for the comparator arms (to maintain
blinding) and, therefore, the impact of the placebo on adherence
could not be measured. We chose to exclude trials that used self-
reported adherence as the patients are more likely to overe-
stimate adherence due to social desirability and typically these
trials do not reﬂect true variability in adherence due to a ceiling
effect [27–30].
Validity Assessment
We used the Cochrane Collaboration’s tool for assessing the risk
of bias for quality assessment of the included studies [31]. The
studies were graded based on the following: sequence genera-
tion, blinding of outcome assessor, incomplete outcome data,
selective outcome reporting, and other sources of bias. The
other sources of bias considered whether the analysis was inten-
tion-to-treat. We summarized the global assessment for each
trial as low risk, unclear, or high risk of bias.
Data Extraction
Three reviewers (O. A. U., J. J. P., and J. B. N.) independently
evaluated the eligibility and methodological quality of studies
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obtained from the literature search. These same reviewers also
independently extracted and compared the data. For each iden-
tiﬁed study that met the selection criteria, details on study de-
sign, study population characteristics, intervention, outcome
measures, and study quality were extracted. Discrepancies
were resolved by consensus through discussion.
Summary Measures
The primary measures of treatment effects were weighted mean
difference (WMD) with 95% conﬁdence interval (CI) for adher-
ence to treatment and relative risk (RR) with 95% CI for viro-
logical suppression. We used the following methods to compute
effect sizes, when incompletely reported: contact with the cor-
responding author; estimation of the standard deviation (SD)
on the basis of the sample size, median, and range as suggested
by Hozo and colleagues [32] or on the basis of the sample size
and P value; and imputation of the SD reported in similar
studies.
Statistical Analysis
The Spearman rank correlation coefﬁcient (rho) was used to ex-
amine the associations between regimen pill burden (daily
number of tablets), length of follow-up period, adherence
rates, and virological response.
We used DerSimonian and Laird [33] random effect models
to synthesize results across studies due to anticipated heteroge-
neity resulting from the differences in methodology, population,
and ART regimen. Between-study heterogeneity was assessed
using the I2 statistic, which reports the percentage of total var-
iation across studies due to heterogeneity rather than chance
[34, 35]. Based on a signiﬁcant interaction previously found in
the meta-analysis by Parienti et al [12], subgroup analyses were
prespeciﬁed to explore the reasons for heterogeneity. These were
based on patient characteristics at baseline, including the
following: treatment-naive individuals initiating their ﬁrst
regimens of ART, treatment-experienced individuals with viro-
logical suppression, and treatment-experienced individuals
with treatment failure (ie, lack of virological suppression).
We examined the reliability and conclusiveness of the avail-
able evidence using a trial sequential analysis (TSA) [36–39]
and the sample size required for a reliable and conclusive meta-
analysis. Therefore, we calculated the sample size (ie, the
heterogeneity-corrected optimal information size [HOIS]) re-
quired to detect or reject a once-daily regimen intervention
effect of minimal relevant difference of 2 percentage points in
mean adherence and a 10% RR difference in viral suppression.
We then used the HOIS to construct Lan-DeMets sequential
monitoring boundaries for our cumulative metaanalyses analo-
gous to interim monitoring in an RCT [36–39]. We conducted
the TSA with the intention of maintaining an overall 5% risk of
a type I error and 20% risk of a type II error.
This review was performed according to the PRISMA recom-
mendations for meta-analyses of RCTs [40]. Stata 12 (Stata
Corporation, College Station, TX) and Review Manager 5.2
software (http://ims.cochrane.org/revman) were used for
meta-analysis; Trial Sequential Analysis Software, version 0.9
beta (www.ctu.dk/tsa), was used for the trial sequential analyses.
RESULTS
Study Selection and Characteristics
The literature search yielded 428 articles (Figure 1). After re-
view, 46 articles were selected for critical reading. Of the 46 ar-
ticles, 27 did not meet the inclusion criteria and were excluded.
Nineteen studies [5, 17–19, 21, 22, 24, 41–49, 51–53 ] with useable
outcome data involving 6312 individuals met the inclusion crite-
ria and were included. Table 1 shows the characteristics of the in-
cluded studies. The studies were published between 2004 and
2011; 11 studies with 3029 patients were included in the ear-
lier meta-analysis [12] and 8 additional studies with 3283 patients
Figure 1. Study selection ﬂow diagram. Abbreviations: QD, once daily;
RCT, randomized controlled trial; TID, three times a day.
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were identiﬁed. Most studies (18/19; 95%) were published in
peer-reviewed journals. Seven studies (37%) included treat-
ment-naive patients, 9 (47%) evaluated treatment-experienced
patients with suppressed viral loads, and 3 (16%) evaluated treat-
ment-experienced patients with unsuppressed viral loads. The
median duration of follow-up was 48 weeks (range, 4–96
weeks). Most studies (N = 17; 89%) reported both adherence
and virological suppression. Eleven studies (58%) used MEMS
to measure adherence, and 8 studies used pill count ratio. Supple-
mentary Table 1 shows the characteristics of studies that were ex-
cluded from the meta-analysis, and Supplementary Table 2 shows
the assessment of bias risk among the included studies.
Pill Burden
There was a negative and statistically signiﬁcant association
(Figure 2A) between adherence and pill burden (Spearman
Table 1. Characteristics of Studies Included in a Meta-Analysis of Once-Daily vs Twice-Daily Antiretroviral Therapy Regimens
Study Year
Once-Daily
Regimen
Twice-Daily
Regimen Population
Follow-
up,
weeks
Means of
Assessing
Adherence
Outcomes
Reported
Risk
of
Bias
Benson [41] 2004 FTC, D4T or AZT,
and an NNRTI
or a PI
3TC, D4T or AZT, and an
NNRTI or a PI
Experienced-
controlled
48 Pill count Both Low
Eron [43] 2004 LPV/r and NRTIs LPV/r and NRTIs Treatment-
naive
48 MEMS Both Low
Sosa [53] 2005 ABC, 3TC, and a PI
or NNRTI
ABC, 3TC, and a PI or
NNRTI
Experienced-
controlled
48 Pill count Both Low
Gallant [5] 2006 TDF, FTC, and EFV AZT, 3TC, and EFV Treatment-
naive
48 Pill count Both Low
Kubota [44] 2006 ABC, 3TC, and a
third agent
ABC, 3TC, and a third
agent
Treatment-
naive
12 MEMS Adherence Low
LaMarca [45] 2006 ABC/3TC (FDC) +
TDF +New
NNRTI or PI
ABC + 3TC + TDF + new
NNRTI or PI
Experienced-
failing
48 Pill count Both Low
Portsmouth [51] 2006 D4T XR, 3TC, and
EFV
D4T or AZT, 3TC,
and EFV
Experienced-
controlled
24 MEMS Both Low
Ruane [52] 2006 AZT, 3TC, ABC and
EFV
AZT, 3TC, ABC and EFV Experienced-
controlled
24 MEMS Both Low
Molina [48] 2007 LPV/r, TDF and
FTC
LPV/r, TDF and FTC Treatment-
naïve
96 MEMS Both Low
Parienti [49] 2007 NVP and NRTIs NVP and NRTIs Experienced-
controlled
16 MEMS Both Low
Boyle [42] 2008 D4T XR, 3TC, and
EFV
NRTIs and PI or NNRTI Experienced-
controlled
48 MEMS Both Low
Maitland [46] 2008 ABC and 3TC ABC and 3TC Experienced-
controlled
4 MEMS Both Low
Molina [47] 2008 ATV/r plus TDF-
FTC
LPV/r plus TDF-FTC Treatment-
naïve
48 Pill count Both High
Campo [24] 2010 EFV plus NRTIs EFV plus NRTIs Experienced-
controlled
48 Pill count Both Low
Flexner [22] 2010 LPV/r and NRTIs LPV/r and NRTIs Treatment-
naïve
48 MEMS Both Low
Gonzalez-Garcia [21] 2010 LPV/r, FTC, and
TDF
LPV/r, FTC, and TDF Treatment-
naïve
96 MEMS Both Low
Zajdenverg [19] 2010 LPV/r and NRTIs LPV/r and NRTIs Experienced-
failing
48 MEMS Both Low
Arasteh [18] 2011 NPV XR plus NRTIs NPV IR plus NRTIs Experienced-
controlled
24 Pill count Both Low
Cahn [17] 2011 DRV/r and NRTIs DRV/r and NRTIs Experienced-
failing
48 Pill count Both Low
The generation of the allocation sequencewas adequately reported in 8 studies (42%) and inadequately reported in 11 studies (58%). Potential risk of bias likely to be
introduced by incomplete datawas low in 16 studies (84%), unclear in 2 studies (11%), and high in 1 study [47] (imbalanced loss to follow-up). Therewas evidence of
selective reporting in 3 studies (16%) that reported adherence alone. Most studies used intention to treat analysis (n = 18, 95%).
Abbreviations: 3TC, lamivudine; ABC, abacavir; ATV/r, atazanavir/ritonavir; AZT, zidovudine; d4T, stavudine; DRV/r, darunavir/ritonavir; EFV, efavirenz; FDC, fixed-dose
combination; FTC, emtricitabine; LPV/r, lopinavir/ritonavir; MEMS, Medication Event Monitoring System; NA, not applicable; NNRTI, non-nucleoside reverse-
transcriptase inhibitor; NRTIs, nucleoside reverse-transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; TDF, tenofovir; XR, extended release.
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correlation = −0.45; 95% CI, −.67 to −.16; P = .004) for both
once-daily and twice-daily regimens. However, when the anal-
ysis was stratiﬁed by the regimens, the association between ad-
herence and pill burden was signiﬁcant in the twice-daily
regimens (Spearman correlation =−0.67; 95% CI, −.86 to −.37;
P = .001) but not in the once-daily regimens (Spearman corre-
lation = −0.22; 95% CI, −.60 to .25; P = .35). There was also a
statistically signiﬁcant negative association (Figure 2B) between
pill burden and virological suppression (Spearman cor-
relation = −0.70; 95% CI, −.84 to −.49; P < .0001), which was
signiﬁcant in both the once-daily (Spearman correla-
tion = −0.63; 95% CI, −.85 to −.23; P = .005) and twice-daily
subgroups (Spearman correlation = −0.75; 95% CI, −.90 to
−.44; P = .0003).
Once-Daily Dosing
When all populations were combined, mean adherence was
slightly higher among participants following once-daily
regimens than those; following twice-daily regimens (WMD =
2.55%; 95% CI, 1.23–3.87; P = .0002; Figure 3). The trial se-
quential analysis demonstrated that for the regimens evaluated,
the meta-analysis was conclusive (Supplementary Figure 1). In
prespeciﬁed subgroup analyses, the greater average adherence
with once-daily vs twice-daily dosing was more pronounced
in treatment-naive patients (WMD = 3.94%; 95% CI, 1.42–
6.47; P = .002; Figure 3) and treatment-experienced patients
with virological failure switching to once-daily dosing
(WMD = 5.28%; 95% CI, .60–9.96; P = 0.03; Figure 3) than in
treatment-experienced patients who switched (for simpliﬁcation/
convenience) when their viral load was suppressed (WMD =
0.97%; 95% CI, .38–1.55; P = 0.53, Figure 3). These differences
between subgroups were statistically signiﬁcant (P = .02 for in-
teraction). There was no signiﬁcant difference in virological
suppression among patients following once-daily vs twice-
daily regimens (RR = 1.01; 95% CI, .98–1.03; P = .57; I2 = 0%,
Figure 4). Trial sequential analysis suggested that as of
2007 (after the ninth trial), sufﬁcient evidence had accrued to
demonstrate that the likelihood of ﬁnding a treatment effect
was too low to justify further data collection. We therefore
conclude that any possible intervention effect of once-daily reg-
imens vs twice-daily regimens is lower than a 10% RR reduction
in virological suppression (the prespeciﬁed threshold; Supple-
mentary Figure 2). Furthermore, there was no signiﬁcant diffe-
rence between once- and twice-daily regimens in virological
suppression in the treatment-naive or -experienced subgroups
(Figure 4).
Duration of Follow-up and Treatment Effects
Adherence declined signiﬁcantly over time (Spearman correla-
tion = −0.41; 95% CI, −.64 to −.11; P = .009; Supplementary
Figure 2. Antiretroviral therapy adherence rate, virological response, and pill burden. Area of circle is proportional to the sample size. Blue, once-daily
regimens; orange, twice-daily regimens.
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Figure 3A). When the analysis was stratiﬁed by dosing regi-
mens, twice-daily remained statistically signiﬁcant (Spearman
correlation = −0.50; 95% CI, −.80 to −.03; P = .04), whereas
the once-daily was not (Spearman correlation = −0.368;
95% CI, .697 to .088; P = .110). Similarly, there was a signiﬁcant
negative association (Supplementary Figure 3B) between
virological suppression and duration of follow-up (Spearman
correlation =−0.700; 95% CI, −.836 to −.482; P < .0001), such
that virological suppression declined with longer follow-up. The
associations were similar to the overall for both twice-daily
(Spearman correlation = −0.692; 95% CI, −.876 to −.333;
P = .002) and once-daily (Spearman correlation =−0.709; 95%
CI, −.833 to −.362; P = .001) regimens.
Of note, in a post hoc sensitivity analysis, inclusion of studies
with self-reported adherence or virological outcomes only did
not materially change our results (data not shown).
DISCUSSION
This meta-analysis of 19 RCTs which included 6312 patients
found that higher pill burden was associated with both lower
adherence and worse virological suppression in both twice-
daily and once-daily subgroups. In addition, adherence was
higher with once-daily ART regimens than with twice-daily reg-
imens when adherence was measured objectively using pill
counts and/or MEMS caps. However, this difference was mini-
mal and did not translate into better treatment outcomes. Fur-
thermore, the greater adherence with once-daily dosing was
only statistically signiﬁcant in treatment-naive individuals and
in those who switched from twice- to once-daily dosing with vi-
rological failure. Adherence did not increase among treatment-
experienced patients who switched from twice- to once-daily
dosing while virologically suppressed; adherence was likely
Figure 3. Forest plot of the effect of once-daily vs twice-daily antiretroviral regimens on the rate of adherence. Abbreviations: CI, conﬁdence interval; IV,
inverse variance; SD, standard deviation.
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high in these patients prior to the switch. Both adherence and
virological suppression decreased with longer follow-up, but the
adherence decrease was less pronounced with once-daily dosing
than with twice-daily dosing.
Interestingly, none of the included randomized trials directly
evaluated the effect of an STR, which we consider an unan-
swered question for further research. However, in our study,
there was a signiﬁcant negative association between pill burden
and virological suppression, suggesting that regimen simpliﬁca-
tion with STRs may be helpful in select situations. One small
observational study conducted among marginally housed indi-
viduals and 2 large observational studies conducted found bet-
ter adherence with STRs (compared with all other regimens,
whether once daily or twice daily) [55, 56, 57], while 2 other ob-
servational studies found no difference between STRs and other
once-daily regimens among patients starting ART [58] or
among those who were switched from STR to multitablet regi-
mens for reasons of cost [59].
There are several possible explanations for the apparent lack
of impact of once- vs twice-daily dosing on virological out-
comes. First, the impact of once-daily dosing on adherence
was relatively small (2.5% absolute increase in adherence);
this was possibly too small to result in a clinically meaningful
difference in virological suppression. Second, a substantial
number of the trials included in this meta-analysis were of rel-
atively short duration. Moreover, volunteers for clinical trials
Figure 4. Forest plot of the effect of once-daily vs twice-daily antiretroviral regimens on virologic suppression (plasma RNA HIV level <50 or <200 copies/mL).
Abbreviations: CI, conﬁdence interval; HIV, human immunodeﬁciency virus; M-H, Mantel-Haenszel.
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are likely to be more adherent than their counterparts managed
in routine clinical practice, and there may be more resources
available to support adherence in clinical trial settings [60].
For these reasons, the difference in virological suppression
that we found between once- and twice-daily ART regimens
may be underestimated.
These results have several important practical implications.
Currently, as all recommended regimens are highly potent,
ART combinations should be selected based on factors such
as tolerability, potential drug interactions, patient preference
for dosing frequency, and pill burden, as well as structural fac-
tors (eg, cost, drug availability, access to care, insurance cover-
age) [61]. Efforts to improve and sustain adherence should not
be limited to regimen simpliﬁcation, but consideration should
be given to proven evidence-based interventions to improve ad-
herence such as social support [62], adherence support toolkits
(eg, pillbox organizers) [63], use of cell phone and/or text mes-
sages, treatment supporters, and other targeted interventions
when necessary [64–68].
In a mathematical simulation, Walensky and colleagues
showed that the future use of a once-daily regimen that includes
generic efavirenz plus generic lamivudine plus branded tenofo-
vir in the United States could yield savings of almost $1 billion
per year to HIV programs [69]. Our results suggest that these
savings may be counterbalanced, in part, by worse virological
outcomes if an increase in pill burden is required. However,
no study, including ours, was speciﬁcally designed to directly
investigate the impact of desimpliﬁcation involving switching
patients from once-daily STR to once-daily ART regimens con-
taining multiple tablets. Further research is urgently needed to
address this question.
Our study has several strengths. We performed a comprehen-
sive search of several databases and sources to identify eligible
RCTs that provide the highest quality of evidence. Three au-
thors independently evaluated each study for inclusion and
data extraction. Furthermore, we performed a trial sequential
analysis; this is an efﬁcient decision-making tool that is used
to establish whether ﬁrm evidence of effect has been obtained
[70]. Regarding limitations, most studies were of good quality
with a low risk of bias. However, to the extent that their evi-
dence was potentially biased, those biases are mirrored in our
analyses. Notably, the likelihood of attrition bias, with a system-
atic difference between the 2 regimens in withdrawal rates, was
very high in 1 study. While there was no evidence of heteroge-
neity in assessing virological suppression, the level of heteroge-
neity between studies in assessing adherence rates was high
(I2 > 50%). Also, by focusing on once-daily vs twice-daily dos-
ing, our analysis may have masked regimen-speciﬁc effects (eg,
differences in toxicity) that have little to do with the frequency
of dosing. Finally, the impact of regimen frequency and pill bur-
den on adherence and virological outcomes in RCTs may not
necessarily generalize to desimpliﬁcation, in which patients
may perceive that their regimen has been reduced in quality.
Such a change could adversely affect adherence and/or treat-
ment outcome, and, as noted above, speciﬁc studies to investi-
gate this question are needed.
In this meta-analysis of 19 RCTs, we conﬁrmed that once-
daily ART regimens increased adherence when compared
with twice-daily regimens, but the difference was modest and
not associated with a difference in virological suppression. Im-
portantly, we found that higher pill burden was associated with
lower rates of virological suppression regardless of dosing fre-
quency. The nonlinear correlation between pill burden and ad-
herence or virological suppression suggests that, while ART
desimpliﬁcation from once-daily STRs to once-daily multitablet
regimens may have adverse effects on virological outcomes, sep-
arating out STRs and/or ﬁxed-dose combinations into their
constituents is not likely to have a major detrimental impact
on virological outcomes (provided that the overall pill burden
does not increase dramatically). Nevertheless, further research
is needed to directly investigate the impact of such a switch,
in particular among patients who are virologically suppressed
at baseline. In the meantime, our results suggest that pill burden
should be a consideration in the selection of an antiretroviral
regimen, independent of dosing frequency.
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